WuXi XDC

Shanghai – October 15, 2026 -- WuXi XDC (2268.HK) has won "Best CDMO" at the 2026 World ADC Awards for the fourth consecutive year and "Best CRO" for the second, making it the only contract research, development and manufacturing organization (CRDMO) to take both titles two years running.

WuXi XDC reports record 51 new iCMC projects in first half of 2026

According to the company's 2026 interim results, WuXi XDC had more than 810 global clients as of June 30, 2026. Fifteen of the top 20 pharmaceutical companies by revenue are among its partners. The company has helped clients submit more than 160 IND applications and now holds 328 iCMC projects. The 51 signed in the first half of 2026 are a record.

Headcount exceeds 3,600, and more than 50% of employees hold a master's degree or higher.

Singapore – September 21, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has secured GMP release for its Singapore manufacturing site at Tuas Biomedical Park, marking the bioconjugate CRDMO's first overseas facility just two and a half years after the site was announced in March 2024.

BCM3 dual-function line and DP4 drug product facility clear GMP release

The 25,000-square-meter site achieved GMP release for both its BCM3 antibody intermediate and conjugated drug substance production line and its DP4 drug product facility in August 2026. BCM3 supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances, operating under FDA, EMA and NMPA standards. A second line, BCM4, is slated for GMP release by the end of 2026 with a maximum single-batch capacity of 500 L for conjugated drug substance.

Shanghai – September 20, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.

Deal structure includes upfront payment, milestones and tiered royalties

The agreement grants Ona Therapeutics exclusive global rights to develop an ADC candidate using WuXi XDC's WuXiTecan-2 platform. The total potential deal value comprises an upfront payment plus development, regulatory and sales milestone payments, with WuXi XDC also eligible for tiered royalties on net sales once the resulting product reaches commercialization. WuXi XDC will additionally provide chemistry, manufacturing and controls (CMC) development and manufacturing support through its integrated ADC CRDMO platform.